QuidelOrtho and BÜHLMANN Laboratories have announced the availability of the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's VITROS systems as a Microtip partnership assay (MPA).
Both particle-enhanced turbidimetric immunoassays, the fCAL turbo assay for faecal calprotectin measurement aids in the diagnosis of inflammatory bowel disease (IBD) and its differentiation from irritable bowel syndrome, and the fPELA turbo assay for faecal pancreatic elastase aids in the determination of pancreatic insufficiency.
This collaboration addresses key healthcare trends, including the rise of non-invasive diagnostic tools, the demand for cost-effective healthcare solutions, and the growing focus on gastrointestinal and pancreatic health and its systemic impact. The fCAL and fPELA turbo assays demonstrate innovation in diagnostics technology, supporting the shift toward tailored medicine and preventive healthcare.
The fCAL and fPELA turbo assays are both now available for use on QuidelOrtho's VITROS XT 7600 and 5600 Integrated System, as well as VITROS 4600 Chemistry Systems.
Key features include:
- Rapid results in less than 10 minutes
- Wide reportable ranges
- 90-day on-analyser stability
- Compatibility with VITROS Automation Solutions
- Simplified sample extraction and preparation with CALEX Cap technology.
"The integration of BÜHLMANN's fCAL and fPELA turbo assays with our VITROS systems represents a significant advancement in IBD and pancreatic insufficiency diagnoses," said Jonathan Siegrist PhD, Executive Vice President of Research & Development & Chief Technology Officer at QuidelOrtho. "This collaboration allows laboratories to provide fast results to aid in the diagnosis and management of IBD and pancreatic issues. With features like the long calibration interval and the ability to use the CALEX Cap–prepared stool samples directly, we're offering a solution that combines clinical accuracy with operational efficiency, ultimately improving patient care."
These assays contribute to better management of gastrointestinal health, reducing the need for invasive procedures and lowering long-term healthcare costs. Both assays utilise BÜHLMANN's innovative CALEX Cap technology, which simplifies sample extraction and preparation while facilitating safe handling – all integrated onto a single VITROS system.